Literature DB >> 12881194

PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing.

Z Gao1, A N Lukyanov, A R Chakilam, V P Torchilin.   

Abstract

Mixed micelles were prepared from poly(ethyleneglycol)-distearyl phosphoethanolamine (PEG2000-PE) and egg phosphatidylcholine. The micelles were covalently modified with the nucleosome-specific monoclonal antibody 2C5 known to recognize and bind a variety of tumor cells via their surface-bound nucleosomes. Covalent attachment of 2C5 antibody was performed via a micelle-incorporated PEG-PE with the distal terminus of the PEG block activated with p-nitrophenylcarbonyl group (pNP-PEG-PE). Micelle surface-attached 2C5 antibody maintained its specific activity. 2C5-targeted immunomicelles were able to carry more than 3 wt% of taxol. Taxol-loaded immunomicelles specifically recognized tumor cell lines of several types. The cytotoxicity of 2C5-targeted taxol-loaded immunomicelles in a cell culture model was much higher when compared with free taxol or taxol in non-targeted micelles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12881194     DOI: 10.1080/1061186031000138623

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  17 in total

1.  An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution.

Authors:  Xiankai Sun; Raffaella Rossin; Jeffrey L Turner; Matthew L Becker; Maisie J Joralemon; Michael J Welch; Karen L Wooley
Journal:  Biomacromolecules       Date:  2005 Sep-Oct       Impact factor: 6.988

2.  Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.

Authors:  Federico Perche; Niravkumar R Patel; Vladimir P Torchilin
Journal:  J Control Release       Date:  2012-09-10       Impact factor: 9.776

3.  Palmitoyl ascorbate-loaded polymeric micelles: cancer cell targeting and cytotoxicity.

Authors:  Rupa R Sawant; Onkar Vaze; Gerard G M D'Souza; Karen Rockwell; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2010-08-21       Impact factor: 4.200

4.  Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids.

Authors:  Junping Wang; Dimitry Mongayt; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2005-01       Impact factor: 5.121

Review 5.  Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs.

Authors:  Avinash Gothwal; Iliyas Khan; Umesh Gupta
Journal:  Pharm Res       Date:  2015-09-17       Impact factor: 4.200

6.  Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier.

Authors:  Peng Zhang; Jianqin Lu; Yixian Huang; Wenchen Zhao; Yifei Zhang; Xiaolan Zhang; Jiang Li; Raman Venkataramanan; Xiang Gao; Song Li
Journal:  AAPS J       Date:  2013-11-27       Impact factor: 4.009

7.  Fluorescence anisotropy, FT-IR spectroscopy and 31-P NMR studies on the interaction of paclitaxel with lipid bilayers.

Authors:  Anand Babu Dhanikula; Ramesh Panchagnula
Journal:  Lipids       Date:  2008-05-06       Impact factor: 1.880

8.  Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity.

Authors:  Rupa R Sawant; Rishikesh M Sawant; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2008-04-29       Impact factor: 5.571

Review 9.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.